Semaglutide (Ozempic) Approved for Type 2 Diabetes
More than 28 million people in the United States have type 2 diabetes, which occurs when the body can no longer produce the sugar-regulating hormone insulin, or the body can't use insulin properly.
People with type 2 diabetes are two to four times more likely than the average person to develop heart disease, said Novo Nordisk, the maker of the drug.
In clinical trials involving more than 8,000 adults with type 2 diabetes, Ozempic was shown to help users lower A1c, a test that measures the amount of glucose in a person's blood. The drug, when combined with proper diet and exercise, also was shown to help users lose weight, Novo said in a company news release.
The drug's most common side effects include nausea, vomiting, diarrhea, abdominal pain and constipation. Less common but more serious adverse reactions could include thyroid tumors, pancreatitis, changes in vision, kidney failure and serious allergic reactions, the Plainsboro, N.J.-based company said.
As a condition of approval, the FDA is requiring Novo to study the drug's safety and effectiveness in people under 18.
© 2020 HealthDay. All rights reserved.
Posted: December 2017
Read this next
TUESDAY, Oct. 13, 2020 -- A small study suggests that a new procedure that treats part of the intestine just beyond the stomach may allow people with type 2 diabetes to safely...
MONDAY, Oct. 12, 2020 -- Weight-loss surgery significantly reduces the risk of pancreatic cancer in obese people with diabetes, a new study finds. For the study, the researchers...
FRIDAY, Oct. 2, 2020 -- Often-used drugs called proton pump inhibitors (PPIs) ease heartburn symptoms, but a new study suggests they might also increase the risk of type 2...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.